What about going forward? Do you think the results of the FDA-required trial will be in TEVA's favor, and how long would you expect such a trial to take?
I expect that Teva’s program for low-volume Copaxone will now be supplanted by the program for thrice-weekly Copaxone (#msg-58091689).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”